Cornerstone Capital Management Holdings LLC. Cuts Stake in Amicus Therapeutics, Inc. (FOLD)
Cornerstone Capital Management Holdings LLC. decreased its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 12.8% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 68,532 shares of the biopharmaceutical company’s stock after selling 10,100 shares during the period. Cornerstone Capital Management Holdings LLC.’s holdings in Amicus Therapeutics were worth $1,033,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in FOLD. Strs Ohio purchased a new stake in Amicus Therapeutics during the 3rd quarter valued at $102,000. Birchview Capital LP purchased a new stake in Amicus Therapeutics during the 3rd quarter valued at $151,000. Teacher Retirement System of Texas boosted its position in Amicus Therapeutics by 1.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 169 shares during the period. Engineers Gate Manager LP purchased a new stake in Amicus Therapeutics during the 3rd quarter valued at $155,000. Finally, Tudor Investment Corp ET AL purchased a new stake in Amicus Therapeutics during the 2nd quarter valued at $124,000.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) opened at $14.16 on Monday. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22. Amicus Therapeutics, Inc. has a 1-year low of $4.59 and a 1-year high of $16.60. The company has a market cap of $2,281.22, a price-to-earnings ratio of -7.74 and a beta of 1.76.
Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative return on equity of 132.40% and a negative net margin of 1,026.91%. The company had revenue of $10.90 million during the quarter, compared to the consensus estimate of $9.02 million. During the same quarter last year, the company posted ($0.33) earnings per share. The firm’s revenue for the quarter was up 419.0% compared to the same quarter last year. sell-side analysts predict that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.
FOLD has been the subject of several analyst reports. Robert W. Baird reissued an “outperform” rating and set a $16.00 price target on shares of Amicus Therapeutics in a research report on Monday, September 25th. Zacks Investment Research cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 12th. Chardan Capital restated a “buy” rating and issued a $16.50 price objective (down from $17.50) on shares of Amicus Therapeutics in a report on Wednesday, September 13th. Bank of America upped their price objective on shares of Amicus Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, October 4th. Finally, Goldman Sachs Group restated a “neutral” rating and issued a $17.00 price objective on shares of Amicus Therapeutics in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $17.81.
In related news, Director Michael Raab sold 10,000 shares of the stock in a transaction dated Thursday, October 12th. The shares were sold at an average price of $14.25, for a total value of $142,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Daphne Quimi sold 7,000 shares of the stock in a transaction dated Thursday, October 12th. The stock was sold at an average price of $14.25, for a total transaction of $99,750.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 758,224 shares of company stock valued at $10,785,546. 3.40% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This report was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://theolympiareport.com/2017/12/25/cornerstone-capital-management-holdings-llc-cuts-stake-in-amicus-therapeutics-inc-fold.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.